Initial clinical experience with dideoxynucleosides as single agents and in combination therapy.
about
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitroIsolation and characterization of a dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus reverse transcriptaseInhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracilInhibitory Effect of Bridged Nucleosides on Thermus aquaticus DNA Polymerase and Insight into the Binding InteractionsTreatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy.Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in ratsHigh-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance.A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohortDNA polymerases as therapeutic targetsPharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathyTwenty-five years of translational medicine in antiretroviral therapy: promises to keep.Inhibition of Trypanosoma cruzi growth in mammalian cells by purine and pyrimidine analogs.Immunomodulatory and antiviral activities of 2',3'-dideoxy-beta-L-cytidine and 2',3'-dideoxy-beta-L-5-fluorocytidine.Nucleoside transport in primary cultured rabbit tracheal epithelial cells.
P2860
Q24655011-D87279BD-C588-4978-963B-5E25580136DEQ28316326-305276B9-259B-4C5F-8C95-3F7D78F9ADE9Q28324219-9BDF354C-9D8D-4516-8093-BF9AD77C492DQ28379171-F178AC2D-1AB7-41FC-92A4-BD5E587BDABFQ28552963-629C99F7-4A56-4FDC-831C-F1B6E6BD0996Q35232016-2A5EB519-53D4-4064-9CD1-0B5D8D76411CQ35867338-34497ED2-AF5C-4693-9DA9-E3EDBD472701Q36410455-001CFE07-0A54-4E02-BA48-91F7EDCD5745Q36922522-707CC5E4-7359-4FB1-B44D-3FE7E0E4D3ECQ37216862-68C2B8E3-AC0F-4994-BCA1-251F84950019Q37251569-5681823C-70F7-48C0-85D3-29FC243FA76CQ37770831-A9BCCF8E-FB00-4D5C-A41C-6308A0BE3CB0Q39783058-D9821260-3DD6-4F03-846D-A1B8EF46D7E9Q41375344-AA0F9F53-E3A3-4AAA-954B-5F91FA596B46Q46080489-DCFEFFA0-FDAD-4BA0-A1EF-467F655A9FEB
P2860
Initial clinical experience with dideoxynucleosides as single agents and in combination therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Initial clinical experience wi ...... ts and in combination therapy.
@en
Initial clinical experience wi ...... ts and in combination therapy.
@nl
type
label
Initial clinical experience wi ...... ts and in combination therapy.
@en
Initial clinical experience wi ...... ts and in combination therapy.
@nl
prefLabel
Initial clinical experience wi ...... ts and in combination therapy.
@en
Initial clinical experience wi ...... ts and in combination therapy.
@nl
P2093
P2860
P1476
Initial clinical experience wi ...... ts and in combination therapy.
@en
P2093
Yarchoan R
P2860
P304
P356
10.1111/J.1749-6632.1990.TB17853.X
P407
P577
1990-01-01T00:00:00Z